Heparin inhibits osteoclastic differentiation and function

Journal of Cellular Biochemistry

Volumn 103, Issue 6, 2008, Pages 1707-1717

  Ariyoshi, Wataru ^a   Takahashi, Tetsu ^a   Kanno, Takahiro ^b   Ichimiya, Hisashi ^a   Shinmyouzu, Kouhei ^a   Takano, Hiroshi ^c   Koseki, Takeyoshi ^d   Nishihara, Tatsuji ^a,e  

^a KYUSHU DENTAL COLLEGE   (Japan)

^b KAGAWA PREFECTURAL CENTRAL HOSPITAL   (Japan)

^c AKITA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^d TOHOKU UNIVERSITY   (Japan)

^e NONE   (Japan)

Author keywords

Binding; Glycosaminoglycan; Heparin; Osteoclastogenesis; Receptor activator of NF B ligand

Indexed keywords

ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; GLYCOSAMINOGLYCAN; HEPARIN; OSTEOCLAST DIFFERENTIATION FACTOR;

ANIMAL CELL; ARTICLE; CELL CULTURE; CELL DIFFERENTIATION; CELL FUNCTION; CELL GROWTH; CELL PROLIFERATION; COLUMN CHROMATOGRAPHY; ENZYME SUBSTRATE; IMMUNOBLOTTING; MOUSE; NITROBLUE TETRAZOLIUM TEST; NONHUMAN; ONCOGENE SRC; OSTEOCLAST; OSTEOLYSIS; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN EXPRESSION; STAINING; WESTERN BLOTTING;

ACID PHOSPHATASE; ANIMALS; BONE RESORPTION; CELL DIFFERENTIATION; CELL LINE; GENES, SRC; GLYCOSAMINOGLYCANS; HEPARIN; ISOENZYMES; MICE; OSTEOCLASTS; RANK LIGAND; RECOMBINANT PROTEINS;

EID: 41849089744     PISSN: 07302312     EISSN: 10974644     Source Type: Journal    
DOI: 10.1002/jcb.21559     Document Type: Article

References (35)

1. Casu B, Lindahl U. 2001. Structure and biological interactions of heparan sulfate. Adv Carbohydr Chem Biochem 57:159-206.
2. Chen Y, Maguire T, Hileman RE, Fromm JR, Esko JD, Linhardt RJ, Marks RM. 1997. Dengue virus infectivity depends on envelope protein binding to target cell heparan sulfate. Nat Med 3(8):866-871.
3. Chevanne M, Caldini R, Manao G, Ruggiero M, Vannucchi S. 1999. Heparin binding peptides co-purify with glycosaminoglycans from human plasma. FEBS Lett 463(1-2):121-124.
4. c-src to integrin-dependent cytoskeletal complexes in thrombin-stimulated platelets. Mol Cell Biol 13(3):1863-1871.
5. David-Pfeuty T, Nouvian-Dooghe Y. 1990. Immunolocalization of the cellular src protein in interphase and mitotic NIH c-Src overexpresser cells. J Cell Biol 111(6):3097-3116.
6. Folwarczna J, Sliwinski L, Janiec W, Malgorzata Pikul M. 2005. Effects of standard heparin and low-molecular-weight heparins on the formation of murine osteoclasts in vitro. Pharmacol Rep 57(5):635-645.
7. Fry EE, Lea SM, Jackson T, Newman JWI, Ellard FM, Blakemore WE, Abu-Ghazaleh R, Samuel A, King AM, Stuart DI. 1999. The structure and function of a foot-and-mouth disease virus-oligosaccharide receptor complex. EMBO J 18:543-554.
8. Fuller K, Thong JT, Breton BC, Chambers TJ. 1994. Automated three-dimensional characterization of osteoclastic resorption lacunae by stereoscopic scanning electron microscopy. J Bone Miner Res 9(1):17-23.
9. Ginsberg JS, Kowalchuk G, Hirsh J, Brill-Edwards P, Burrows R, Coates G, Webber C. 1990. Heparin effect on bone density. Thromb Haemost 64(2):286-289.
10. c-src in association with intracellular membranes. J Cell Biol 119(4):1003-1013.
11. Hsu H, Lacey DL, Dunstan CR, Solovyev I, Colombero A, Timms E, Tan HL, Elliott G, Kelley MJ, Sarosi I, Wang L, Xia XZ, Elliott R, Chiu L, Black T, Scully S, Capparelli C, Morony S, Shimamoto G, Bass MB, Boyle WJ. 1999. Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand. Proc Natl Acad Sci USA 96(7):3540-3545.
12. Hulett MD, Freeman C, Hamdorf BJ, Baker RT, Harris MJ, Parish CR. 1999. Cloning of mammalian heparanase, an important enzyme in tumor invasion and metastasis. Nat Med 5(7):803-809.
13. Jones G, Sambrook PN. 1994. Drug-induced disorders of bone metabolism. Incidence, management and avoidance. Drug Saf 10(6):480-489.
14. Kind PRN, King EJ. 1954. Estimation of plasma phosphatase by determination of hydrolysed phenol with aminoantipyrine. J Clin Pathol 7(4):322-326.
15. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashino K, Martin TJ, Suda T. 2000. Tumor mecrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interactions. J Exp Med 191(2):275-286.
16. Kotake S, Udagawa N, Takahashi N, Matsuzaki K, Itoh K, Ishiyama S, Saito S, Inoue K, Kamatani N, Gillespie MT, Martin TJ, Suda T. 1999. IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. J Clin Invest 103(9):1345-1352.
17. Lindahl U. 2000. Heparin-from anticoagulant drug into the new biology. Glycoconj J 17(7-9):597-605.
18. Liu D, Shriver Z, Venkataraman G, EI Shabrawi Y, Sasisekharan R. 2002. Tumor cell surface heparan sulfate as cryptic promoters or inhibitors of tumor growth and metastasis. Proc Natl Acad Sci USA 99(2):568-573.
19. +-ATPase trigger apoptotic cell death of osteoclasts. J Bone Miner Res 12(7):1116-1123.
20. Okahashi N, Murase Y, Koseki T, Sato T, Yamato K, Nishihara T. 2001. Osteoclast differentiation is associated with transient upregulation of cyclin-dependent kinase inhibitors p21 (WAF1/CIP) and p27(KIP1). J Cell Biochem 80(3):339-345.
21. Petitou M, Herault JP, Bernat A, Driguez PA, Duchaussoy P, Lormeau JC, Herbert JM. 1999. Synthesis of thrombin-inhibiting heparin mimetics without side effects. Nature 398(6726):417-422.
22. Sasisekharan R, Ernst S, Venkataraman G. 1997. On the regulation of fibroblast growth factor activity by heparin-like glycosaminoglycans. Angiogenesis 1(1):45-54.
23. Sasisekharan R, Venkataraman G. 2000. Heparin and heparan sulfate: Biosynthesis, structure and function. Curr Opin Chem Biol 4(6):626-631.
24. Shinmyouzu K, Takahashi T, Wataru Ariyoshi, Hisashi Ichimiya, Shin Kanzaki, Tatsuji Nishihara. 2007. Dermatan sulfate inhibits osteoclast formation by binding to receptor activator of NF-κB ligand. Biochem Biophys Res Commun 354:447-452.
25. Shriver Z, Liu D, Sasisekharan R. 2002. Emerging views of heparan sulfate glycosaminoglycan structure/activity relationships modulating dynamic biological functions. Trends Cardiovasc Med 12(2):71-77.
26. Shunkla D, Liu J, Blaiklock P, Shworak NW, Bai X, Esko JD, Cohen GH, Eisenberg RJ, Rosenberg RD, Spear PG. 1999. A novel role for 3-O-sulfated heparan sulfate in herpes simple virus 1 entry. Cell 99(1):13-22.
27. Soriano P, Montgomery C, Geske R, Bradley A. 1991. Targeted disruption of the c-src proto-oncogene leads to osteopetrosis in mice. Cell 64(4):693-702.
28. Suda T, Jimi E, Nakamura I, Takahashi N. 1997. Role of 1 α, 25-dihydroxyvitamin D3 in osteoclast differentiation and function. Methods Enzymol 252:223-225.
29. c-src, preferentially on ruffled border membranes. FEBS Lett 313(1):85-89.
30. Teitelbaum SL. 2000. Bone resorption by osteoclasts. Science 289(5484):1504-1508.
31. Vlodavsky I, Friedmann Y, Elkin M, Aingorn H, Atzmon R, Ishai-Michaeli R, Bitan M, Pappo O, Peretz T, Michal I, Specter L, Pecker I. 1999. Mammalian heparanase: Gene cloning, expression and function in tumor progression and metastasis. Nat Med 5(7):793-802.
32. Walenga JM, Bick RL. 1998. Heparin-induced thrombocytopenia, paradoxical thromboembolism, and other side effects of heparin therapy. Med Clin North Am 82(3):635-658.
33. Walton KJ, Duncan JM, Deschamps P, Shaughnessy SG. 2002. Heparin acts synergistically with interleukin-11 to induce STAT3 activation and in vitro osteoclast formation. Blood 100(7):2530-2536.
34. Witt DP, Lander AD. 1994. Differential binding of chemokines to glycosaminoglycan subpopulations. Curr Biol 4(5):394-400.
35. Wolinski-Friedland M. 1995. Drug-induced metabolic bone disease. Endocrinol Metab Clin North Am 24(2):395-420.